Indications
Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
Composition
- Active substance
- telotristat etiprate
- International name (INN)
- telotristat ethyl
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xermelo
- Active substance
- telotristat etiprate
- ATC code
- A16A
- Therapeutic area
- Carcinoid Tumor, Neuroendocrine Tumors
- Marketing authorisation holder
- SERB SAS